2024
The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis G, Correll C, Agorastos A, Sanchez A, Erzin G, Grigoras R, Benussi M, Gondek T, Guloksuz S, Højlund M, Jerotic S, Kilic O, Metaj E, Sidhu D, Skandali N, Skuhareuski A, Tveito M, Wolthusen R, Communication and Publications E, Chumakov E, de Filippis R. The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. The World Journal Of Biological Psychiatry 2024, 25: 342-351. PMID: 38905131, DOI: 10.1080/15622975.2024.2367138.Peer-Reviewed Original ResearchConceptsEuropean Psychiatric AssociationAntipsychotic treatmentPsychiatrists' attitudesTherapeutic drug monitoringEarly-career psychiatristsExploratory factor analysisBenefit of therapeutic drug monitoringPsychiatric AssociationAntipsychoticsNegative expectationsAssociated with frequencyTDM useDrug monitoringTherapeutic drug monitoring useFactor analysisBeliefs of patientsHigh-income countriesLow-/middle-income countriesResponse varianceClinical benefitClozapineOutpatient settingLinear regression analysisClinical settingPsychiatrists
2015
Pharmaceutical industry interactions of psychiatric trainees from 20 European countries
Riese F, Guloksuz S, Roventa C, Fair J, Haravuori H, Rolko T, Flynn D, Giacco D, Banjac V, Jovanovic N, Bayat N, Palumbo C, Rusaka M, Kilic O, Augėnaitė J, Nawka A, Zenger M, Kekin I, Wuyts P, Barrett E, Bausch-Becker N, Mikaliūnas J, del Valle E, Feffer K, Lomax G, Marques J, Jauhar S. Pharmaceutical industry interactions of psychiatric trainees from 20 European countries. European Psychiatry 2015, 30: 284-290. PMID: 25456156, DOI: 10.1016/j.eurpsy.2014.09.417.Peer-Reviewed Original Research
2012
Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsChildCross-Sectional StudiesEuropeEvidence-Based MedicineHealth Care SurveysHumansPractice Patterns, Physicians'PsychiatryPsychotic DisordersSurveys and QuestionnairesConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees
2009
Attitudes and behaviors of psychiatry residents and psychiatrists working in training institutes towards the relationship between the pharmaceutical industry and physicians.
Gülöksüz S, Oral E, Ulaş H. Attitudes and behaviors of psychiatry residents and psychiatrists working in training institutes towards the relationship between the pharmaceutical industry and physicians. Turkish Journal Of Psychiatry 2009, 20: 236-42. PMID: 19757223.Peer-Reviewed Original ResearchConceptsPharmaceutical representativesPrescribing practicesSecond-year residentsHospital staffState hospital staffPhysician prescribing practicesPsychiatry residentsUniversity hospital staffBehavior of physiciansMost physiciansPharmaceutical promotionEducational meetingsDuration of residencyPhysiciansBehaviors of psychiatristsOlder residentsPsychiatristsSignificant interaction